H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Codexis (NASDAQ:CDXS) on Monday, setting a price target of $21, which is approximately 71.71% above the present share price of $12.23.
Ramakanth expects Codexis to post earnings per share (EPS) of -$0.01 for the second quarter of 2020.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in Codexis, with an average price target of $18.25.
The analysts price targets range from a high of $22.5 to a low of $14.
In its latest earnings report, released on 12/31/2019, the company reported a quarterly revenue of $18.65 million and a net profit of $947.00 thousand thousand. The company's market cap is $721.78 million.
According to TipRanks.com, H.C. Wainwright analyst Swayampakula Ramakanth is a 2-star analyst with an average return of -0.5% and a 36.4% success rate.
Codexis, Inc. engages in the discovery, development, and sale of proteins. The company offers enzyme optimization services and developing biocatalyst products. The firm operates through the following segments: Performance Enzymes and Novel Biotherapeutics. Its technologies accelerate the development of manufacturing processes for active pharmaceutical ingredients fine chemicals, agrochemicals, food ingredients, detergents and biofuels. The company was founded in January 2002 and is headquartered in Redwood (NYSE:RWT) City, CA.